List of Excipients in Branded Drug DIPENTUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Viatris Specialty LLC	DIPENTUM	olsalazine sodium	0037-6860	CARAMEL
Viatris Specialty LLC	DIPENTUM	olsalazine sodium	0037-6860	FERROSOFERRIC OXIDE
Viatris Specialty LLC	DIPENTUM	olsalazine sodium	0037-6860	GELATIN
Viatris Specialty LLC	DIPENTUM	olsalazine sodium	0037-6860	MAGNESIUM STEARATE
Viatris Specialty LLC	DIPENTUM	olsalazine sodium	0037-6860	TITANIUM DIOXIDE
Carilion Materials Management	DIPENTUM	olsalazine sodium	68151-0312	CARAMEL
Carilion Materials Management	DIPENTUM	olsalazine sodium	68151-0312	FERROSOFERRIC OXIDE

DIPENTUM Excipient Strategy and Commercial Opportunities for Olsalazine Sodium

Last updated: September 4, 2026

Dipentum contains olsalazine sodium, a colon-targeted prodrug used for maintenance of remission in ulcerative colitis. Its commercial opportunity is primarily a low-cost generic or differentiated oral-solid-dose product rather than a new chemical-entity play. The formulation advantage is that olsalazine’s colon targeting is built into its azo-linked molecular structure, reducing the need for complex enteric polymers or multiparticulate delivery systems. The main development risks are high dose burden, gastrointestinal intolerance, powder-processing performance, capsule stability, and limited market size.

What is Dipentum and how does olsalazine sodium work?

Dipentum is an oral capsule containing olsalazine sodium. The FDA-approved indication is the maintenance of remission in adults with ulcerative colitis. The recommended adult dose is generally 1,000 mg per day, administered as 500 mg twice daily, although titration may be used to reduce treatment-related diarrhea.[1]

Olsalazine consists of two 5-aminosalicylic acid, or 5-ASA, moieties linked by an azo bond. Colonic bacteria cleave that bond, releasing mesalamine locally in the colon. The active pharmaceutical ingredient therefore provides a built-in targeting mechanism that distinguishes olsalazine from conventional immediate-release tablets containing unmodified mesalamine.[2]

The commercial value proposition is concentrated in:

• A non-steroidal maintenance option for ulcerative colitis.
• Colon delivery without a conventional enteric coating.
• A capsule dosage form with established clinical and regulatory precedent.
• Potentially simpler manufacturing than coated mesalamine products.

The commercial limitation is that olsalazine can cause dose-related diarrhea, particularly during treatment initiation. This tolerability issue affects adherence and creates the main rationale for formulation differentiation.[1]

What excipients are used in Dipentum capsules?

The reference formulation uses a conventional hard-gelatin capsule platform. Public product information identifies excipient categories that include microcrystalline cellulose, povidone, crospovidone, magnesium stearate, colloidal silicon dioxide, sodium lauryl sulfate, and talc, with capsule-shell components such as gelatin and colorants.[1,3]

Formulation function	Likely excipient role	Commercial relevance
Diluent and compression or fill aid	Microcrystalline cellulose	Controls fill weight and powder flow
Binder	Povidone	Improves granule or powder cohesion
Disintegrant	Crospovidone	Supports capsule-plug breakup after shell dissolution
Glidant	Colloidal silicon dioxide	Improves flow and reduces weight variation
Lubricant	Magnesium stearate	Reduces tooling or capsule-filling friction
Wetting agent	Sodium lauryl sulfate	Supports wetting of the drug-excipient mass
Anti-adherent or processing aid	Talc	May assist flow and reduce sticking
Shell	Gelatin, pigments, and opacifier	Provides the marketed capsule presentation

The exact qualitative and quantitative composition should be established from the current reference-product labeling and reverse-engineering work before product development. The public label provides a starting point for excipient selection, not a substitute for a formulation development program.

What is the best excipient strategy for a generic Dipentum product?

The lowest-risk strategy is a capsule formulation that closely reproduces the reference product’s critical performance characteristics. A generic developer does not need to duplicate every excipient at the same concentration, but it should preserve the product’s physical, chemical, and dissolution behavior.

Use a simple immediate-release capsule platform

Olsalazine’s azo bond is cleaved in the colon by bacterial enzymes. The drug does not require a conventional polymeric enteric coat to release mesalamine in the colon. A conventional capsule filled with a rapidly dispersing powder blend is therefore the most direct platform.

A simple formulation can offer:

• Lower manufacturing complexity.
• Fewer coating-related scale-up risks.
• Lower capital requirements.
• More predictable capsule-filling operations.
• A shorter development path than a multiparticulate or coated dosage form.

The formulation should avoid unnecessary release-controlling polymers unless comparative data show a meaningful improvement in tolerability or product performance.

Control powder flow and capsule-fill uniformity

Olsalazine sodium is administered at a relatively high daily dose. At 500 mg per capsule, patients generally take two capsules daily. The drug load creates pressure on bulk density, flow, segregation, and capsule-fill weight.

The main excipient variables are:

• Microcrystalline cellulose grade and particle size.
• Colloidal silicon dioxide concentration.
• Magnesium stearate level and blending time.
• Povidone grade and binder concentration.
• Crospovidone level and distribution.
• Drug-to-excipient ratio.
• Lubrication energy and blend uniformity.

Over-lubrication can slow wetting and dissolution. Excessive glidant can alter powder flow and may increase variability if the formulation segregates. A controlled design-of-experiments program should assess blend uniformity, capsule weight variation, disintegration, dissolution, and stability.

Manage moisture and capsule-shell performance

The finished product should be evaluated for moisture sensitivity, shell brittleness, shell deformation, and storage-related changes in dissolution. Hard-gelatin capsules can become brittle at low relative humidity and soft or tacky at high humidity.

A commercial formulation should establish:

• Water activity and moisture limits.
• Packaging requirements.
• Capsule-shell compatibility.
• Stability under accelerated and long-term conditions.
• Protection against humidity excursions.
• Compatibility with high-speed capsule-filling equipment.

Blister packaging may offer a stronger moisture barrier than standard high-density polyethylene bottles, although the economics depend on market size and supply-chain requirements.

What formulation improvements could create commercial differentiation?

The largest unmet formulation need is tolerability rather than targeting. Olsalazine’s pharmacological activity depends on bacterial cleavage in the colon, while diarrhea may arise from local or systemic exposure before the desired colonic effect is established.[1,2]

Lower-dose initiation and titration packs

A 250 mg capsule can support gradual dose escalation. A starter pack containing 250 mg and 500 mg presentations could address early intolerance and simplify titration. This approach would require a commercially viable market and appropriate regulatory positioning, but it does not require a new chemical entity.

Potential product configurations include:

Product concept	Development burden	Commercial rationale
250 mg capsule	Low	Supports titration and lower initial exposure
500 mg capsule	Low	Matches the established maintenance presentation
Starter pack	Low to moderate	Improves initiation and adherence
Blister-pack presentation	Low	Supports dose compliance and humidity protection
Sprinkle or opened-capsule format	Moderate to high	Could address swallowing difficulty but requires performance validation
Modified-release formulation	High	Could target tolerability but needs new clinical and comparative evidence
Pediatric dosage form	High	Requires population-specific usability and safety support

Avoid unnecessary pH-dependent coatings

A pH-sensitive coating could delay release, but it may not improve the core mechanism because olsalazine already uses bacterial azo-bond cleavage for colon targeting. Enteric coating would increase manufacturing cost and introduce additional critical quality attributes, including coating weight gain, coating uniformity, mechanical integrity, and dissolution across pH stages.

A coated or multiparticulate product could still have commercial value if it produces better tolerability or more consistent delivery. It should be treated as a differentiated reformulation, not as the default generic approach.

Consider excipient simplification

A lactose-free, low-excipient formulation could appeal to patients and prescribers who prefer simpler formulations. The commercial benefit is likely modest because lactose intolerance is not the principal limitation of olsalazine. More important priorities are capsule size, daily pill burden, tolerability, and reliable supply.

A developer should avoid removing sodium lauryl sulfate or the disintegrant without comparative dissolution work. The excipient may be present to improve wetting of the drug mass, particularly if the active has poor dispersibility.

What is the FDA regulatory status of Dipentum?

Dipentum was approved by the FDA under NDA 019351 for ulcerative colitis maintenance therapy.[1] The product is an oral capsule containing olsalazine sodium. It is not a biologic, so biosimilar pathways do not apply.

A generic competitor would generally pursue an abbreviated new drug application, or ANDA, referencing Dipentum as the reference listed drug if the product is eligible and commercially listed in the relevant FDA databases. The principal regulatory package would focus on:

• Pharmaceutical equivalence.
• Bioequivalence or an FDA-accepted alternative approach.
• Comparative dissolution.
• Manufacturing controls.
• Stability.
• Labeling.
• Capsule composition and inactive-ingredient acceptability.

Because the product is an orally administered immediate-release capsule, the regulatory pathway is less complex than for an extended-release product. A differentiated dosage form, such as a multiparticulate or modified-release product, could require a full 505(b)(2) strategy rather than a conventional ANDA.

What patents and exclusivity protect Dipentum?

Dipentum is an older small-molecule product. Its original patent and regulatory exclusivity periods have expired, and the product does not have the exclusivity profile of a recently approved drug. Commercial protection is therefore expected to depend on manufacturing know-how, product availability, customer contracts, formulation improvements, and regulatory execution rather than blocking composition-of-matter rights.

Protection category	Relevance to Dipentum
Composition-of-matter patent	Expected to be expired
Original formulation patent	Expected to be expired or commercially weak
FDA orphan exclusivity	Not the principal protection for this product
New formulation patent	Possible for a genuinely differentiated dosage form
Method-of-use patent	Potentially limited because the core indication is established
Manufacturing-process patent	Possible, but generally narrow
Regulatory exclusivity	Not expected to block a conventional generic indefinitely
Orange Book patent litigation	No major active barrier is apparent from the mature product profile

A generic developer should still conduct a current Orange Book and patent-docket review before filing. Paragraph IV risk is likely to arise from a developer challenging any listed formulation or method-of-use patent rather than from a basic olsalazine sodium composition patent.

Which companies could challenge or commercialize Dipentum?

The likely competitive field includes:

• Generic manufacturers with capsule-filling and oral-solid-dose capacity.
• Specialty gastrointestinal companies with established prescriber access.
• Contract development and manufacturing organizations seeking niche products.
• Authorized-generic or license partners connected to the reference-product holder.
• Companies with mesalamine portfolios seeking a lower-cost 5-ASA product.

The product is more attractive to a focused specialty or generic company than to a large pharmaceutical company seeking blockbuster revenue. Its value increases when the developer already has:

• A gastrointestinal sales force.
• A low-cost capsule manufacturing network.
• Existing relationships with specialty pharmacies.
• A portfolio of mesalamine or inflammatory bowel disease products.
• The ability to serve low-volume products without excessive overhead.

What commercial opportunities exist for olsalazine sodium?

The strongest opportunity is a reliable, competitively priced generic capsule. The market is likely to be niche because mesalamine products, sulfasalazine, corticosteroids, immunomodulators, and biologics compete for ulcerative-colitis treatment and maintenance use.[4]

Generic replacement

A conventional generic can compete on:

• Price.
• Availability.
• Wholesaler coverage.
• Medicaid and managed-care contracting.
• Supply reliability.
• 250 mg and 500 mg presentation availability.

The key risk is market erosion from the limited number of patients who remain on olsalazine and the availability of alternative 5-ASA products.

Specialty-packaging opportunity

A blistered 250 mg and 500 mg product could support titration and adherence. This may be commercially useful where the reference product is unavailable or where pharmacy substitution creates supply gaps.

Reformulation opportunity

A reformulated product may justify a 505(b)(2) strategy if it demonstrates a meaningful improvement in:

• Diarrhea incidence.
• Treatment initiation.
• Dose escalation.
• Swallowability.
• Adherence.
• Storage stability.
• Administration flexibility.

The clinical and regulatory burden would be materially higher than for a standard ANDA. A reformulation should therefore be supported by a clear commercial hypothesis rather than excipient novelty alone.

How strong is the patent estate and what are the generic launch risks?

The patent estate is weak as a barrier because Dipentum is a mature small-molecule product. The principal launch risks are commercial and technical:

1. Small or declining patient demand.
2. Intense price competition from generic 5-ASA products.
3. Dose-related diarrhea and discontinuation.
4. Difficulty achieving consistent capsule-fill performance at high drug load.
5. Supply-chain interruptions for specialized raw materials or capsule shells.
6. Limited reimbursement leverage.
7. The need to maintain inventory despite modest demand.
8. Potential regulatory complexity if the developer departs from the reference formulation.

A standard capsule could launch faster and at lower cost than a differentiated delivery system. A modified formulation could command greater value but would require stronger clinical evidence and a more complex regulatory path.

What is the commercial comparison with mesalamine and sulfasalazine?

Attribute	Olsalazine sodium	Mesalamine	Sulfasalazine
Colon-targeting mechanism	Bacterial cleavage of azo bond	Product-dependent, often delayed or controlled release	Bacterial cleavage of azo bond
Main active released in colon	Mesalamine	Mesalamine	Mesalamine plus sulfapyridine
Dosage-form complexity	Moderate	Low to high	Usually conventional oral solid
Main tolerability issue	Diarrhea	Product-dependent GI effects	Sulfapyridine-related adverse effects and intolerance
Generic opportunity	Niche	Broad but competitive	Established and price-sensitive
Reformulation rationale	Improve initiation and tolerability	Optimize release and adherence	Reduce systemic and adverse-effect burden
Biosimilar exposure	None	None	None

Olsalazine has a mechanistic advantage over products that rely entirely on pH-dependent or time-dependent release, but its tolerability profile limits broad substitution. It is best positioned as a targeted generic or specialty product for patients and prescribers who value its colon-delivery mechanism or need an alternative to other 5-ASA products.

Key Takeaways

• Dipentum is an olsalazine sodium capsule approved for maintenance of remission in ulcerative colitis.
• Its colon targeting comes from bacterial cleavage of an azo bond, so a conventional immediate-release capsule is the lowest-risk formulation strategy.
• Microcrystalline cellulose, povidone, crospovidone, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, talc, and gelatin-shell components form the relevant excipient platform.
• The critical development issues are powder flow, capsule-fill uniformity, wetting, dissolution, moisture control, and tolerability.
• A standard generic is more commercially credible than a complex modified-release product.
• The strongest line-extension opportunity is a 250 mg titration presentation or starter pack.
• The patent and exclusivity profile is mature, with limited blocking value expected from original rights.
• Commercial success depends more on supply reliability, pricing, specialty distribution, and differentiated packaging than on patent exclusivity.
• A reformulated product could pursue a 505(b)(2) pathway, but it would need evidence of meaningful clinical or usability improvement.

FAQs

Is Dipentum an extended-release product?

No. Dipentum is an olsalazine sodium capsule whose colon-targeting effect depends primarily on bacterial cleavage of its azo bond, not on a conventional extended-release matrix.

Can a generic Dipentum capsule use different excipients?

Yes. An ANDA product can use different inactive ingredients if it remains pharmaceutically equivalent, meets applicable regulatory requirements, and demonstrates acceptable product performance and safety.

Is olsalazine sodium suitable for an enteric-coated tablet?

It is technically possible, but an enteric coating is not automatically advantageous. The existing molecular targeting mechanism may make a conventional capsule more economical and less complex.

Does Dipentum have biosimilar competition?

No. Olsalazine sodium is a chemically synthesized small molecule, so competition would arise through generic-drug pathways rather than biosimilar development.

What is the most attractive commercial dosage form for olsalazine sodium?

A 500 mg hard capsule remains the most direct commercial product. A 250 mg capsule or titration pack offers the clearest differentiation because it could address early diarrhea and support dose escalation.

References

1. U.S. Food and Drug Administration. (n.d.). Dipentum (olsalazine sodium) capsules: Prescribing information. FDA.
2. National Center for Biotechnology Information. (n.d.). Olsalazine. PubChem Compound Summary.
3. National Library of Medicine. (n.d.). Dipentum- olsalazine sodium capsule. DailyMed.
4. National Institute for Health and Care Excellence. (2024). Ulcerative colitis: Management. NICE guideline.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.